Public disclosures

RLAY insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
Patel Sanjiv

President and CEO · Director · Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 423099 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $15.89 to $16.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

2026-11-192026-11-20

≈ $777,498.26

48,202 shares/units

SEC 4Follow
Bergstrom Donald A

President, R&D · Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 386609 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $16.30 to $16.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. · Includes 5,013 shares underlying restricted stock units.

2026-11-182026-11-20

≈ $169,541.19

10,269 shares/units

SEC 4Follow
Catinazzo Thomas

Chief Financial Officer · Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 70948 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $16.30 to $17.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. · Includes 3,269 shares underlying restricted stock units.

2026-11-182026-11-20

≈ $540,157.67

32,717 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement